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Abstract
BACKGROUND AND PURPOSE: gamma-Hydroxybutyrate (GHB), a natural metabolite of
gamma-aminobutyric acid and a drug used in humans to promote slow-wave sleep and treat narcolepsy,
has been suggested to protect against ischemic stroke at high doses. This study aimed to assess
recovery-promoting effects of GHB at a low dose similar to that used in patients. METHODS: Adult
mice, subjected to 30 min of intraluminal middle cerebral artery occlusion, were intraperitoneally
treated with GHB (100 mg/kg, twice/day, 8 h apart) or saline for 10 days. Motor recovery was evaluated
by the grip strength test. The brain lesion was assessed by cresyl violet and NeuN staining 5 weeks after
stroke. Expression of neuroplasticity-related genes (GAP43, c-jun, neurocan and ephrin B1) was
analyzed by Taqman real-time PCR. RESULTS: GHB-treated mice regained their body weight faster
and recovered grip strength (3 weeks after stroke) more quickly than saline-treated mice. This was
noteworthy as GHB did not influence ischemia-induced brain injury, as revealed by cresyl violet and
neuronal staining. The Taqman PCR assay revealed a decreased expression of c-jun and neurocan in the
ischemic striatum of GHB-treated mice in comparison to saline-treated mice. CONCLUSION: GHB at a
low dose accelerates neurological recovery following ischemic stroke. Further studies are necessary to
determine the potential relationship between GHB, neuroplasticity, sleep and stroke recovery.
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saline-treated mice.  Conclusion: GHB at a low dose acceler-
ates neurological recovery following ischemic stroke. Fur-
ther studies are necessary to determine the potential rela-
tionship between GHB, neuroplasticity, sleep and stroke 
recovery.  Copyright © 2008 S. Karger AG, Basel
 Introduction
  -Hydroxybutyrate (GHB), a natural metabolite of
  -aminobutyric acid, is a neurotransmitter and neuro-
modulator by action on both the GHB receptor and   -
aminobutyric acid type B receptor in the CNS. Exoge-
nously administered GHB that freely crosses the blood-
brain barrier induces diverse neuropharmacological 
effects  [1] including sedation and promotion of deep sleep 
 [2] . Clinically, GHB is an important drug in the treatment 
of such symptoms as cataplexy, excessive daytime sleepi-
ness and sleep disturbance associated with narcolepsy  [3] . 
GHB has been found to have protective action against 
ischemia/brain damage in rat models  [4–8] . However, its 
beneficial effects were observed in studies in which high-
er doses ( 6 300 mg/kg) than those used in patients (60–
130 mg/kg) were applied.
 Ischemic insults trigger considerable changes in the 
expression of neuroplasticity-related genes  [9–11] , many 
 Key Words
 Sodium oxybate   Brain recovery, stroke   Sleep   
Neuroplasticity
 Abstract
 Background and Purpose:   -Hydroxybutyrate (GHB), a nat-
ural metabolite of   -aminobutyric acid and a drug used in 
humans to promote slow-wave sleep and treat narcolepsy, 
has been suggested to protect against ischemic stroke at 
high doses. This study aimed to assess recovery-promoting 
effects of GHB at a low dose similar to that used in patients. 
 Methods: Adult mice, subjected to 30 min of intraluminal 
middle cerebral artery occlusion, were intraperitoneally 
treated with GHB (100 mg/kg, twice/day, 8 h apart) or saline 
for 10 days. Motor recovery was evaluated by the grip 
strength test. The brain lesion was assessed by cresyl violet 
and NeuN staining 5 weeks after stroke. Expression of neu-
roplasticity-related genes ( GAP43, c- jun , neurocan and eph-
rin B1) was analyzed by Taqman real-time PCR.  Results: 
GHB-treated mice regained their body weight faster and re-
covered grip strength (3 weeks after stroke) more quickly 
than saline-treated mice. This was noteworthy as GHB did 
not influence ischemia-induced brain injury, as revealed by 
cresyl violet and neuronal staining. The Taqman PCR assay 
revealed a decreased expression of c- jun and neurocan in 
the ischemic striatum of GHB-treated mice in comparison to 
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with distinct temporal patterns that correspond with ini-
tiation, maintenance and termination phases of post-
stroke axonal sprouting  [12] . These molecular events are 
important, at least in part, for axonal sprouting, tissue 
repair and reorganization and are currently under exten-
sive investigation in search for drug targets to develop 
new therapies to promote stroke recovery. So far there is 
no information whether GHB influences the expression 
of plasticity-related genes.
 In the present study, in a mouse model of focal cerebral 
ischemia  [13] , we aimed to evaluate the effects of GHB at 
a low dose similar to that used in patients on neurological 
recovery from brain injury and the expression of several 
plasticity-related genes, including growth-promoting 
genes  GAP43, c- jun, the growth-inhibiting gene neuro-
can and the developmentally associated growth inhibitor 
ephrin B1, that exhibit a unique early/sustained expres-
sion pattern in response to ischemia  [12] .
 Methods
 Animals and Induction of Focal Striatal Ischemia
 Male C57BL/6J mice, weighing 25.4  8 3 g at the time of sur-
gery, were used in this study. They were housed (4–5 animals/
cage) in standard polycarbonate cages (42.5  ! 26.6  ! 18.5 cm) 
and kept under a 12-hour light/dark cycle (light on at 9 a.m.). Food 
and water were provided ad libitum. All experiments were con-
ducted with governmental approval according to local guidelines 
for the care and use of laboratory animals.
 Focal cerebral ischemia was induced by intraluminal occlu-
sion of the middle cerebral artery (MCA) as described before  [13] . 
Briefly, animals were anesthetized with 1% halothane (30% O 2 , 
remainder N 2 O). The left common carotid artery was exposed 
through a ventral midline cervical incision. A 8-0 silicone-coated 
(Xantopren; Bayer Dental, Osaka, Japan) nylon monofilament 
(Ethilon; Ethicon, Norderstedt, Germany) was inserted into the 
isolated common carotid artery and advanced through the inter-
nal carotid artery up to the bifurcation at which the MCA goes 
off. MCA blood flow was thereby interrupted. Ischemia was mon-
itored by laser Doppler flowmetry via a flexible 0.5-mm fiberoptic 
probe (Perimed, Stockholm, Sweden) that was attached to the in-
tact skull overlying the   MCA territory. Thirty minutes after MCA 
occlusion, the monofilament was retracted, and reperfusion was 
established. Sham control animals were only subjected to the ven-
tral cervical incision under the same anesthesia. Rectal tempera-
ture was maintained at 36.5  8 0.5  °  C by a feedback-controlled 
heating system throughout the entire surgery. The animals were 
placed back into their home cages once they were awake from an-
esthesia.
 Drug Treatment
 At the onset of reperfusion, either 50   l of saline or GHB (100 
mg/kg; Lipomed AG, Arlesheim, Switzerland) were intraperito-
neally applied, followed by twice daily (8 h apart) administrations 
starting at light onset for 10 days. The dose of 100 mg/kg was cho-
sen based on a pilot experiment in which the effects of different 
doses (50–200 mg/kg) on behavior were observed in normal mice. 
No abnormal behavior was induced by the dose of 100 mg/kg. The 
following groups were assessed: (1) ischemic surgery followed by 
GHB treatment (n = 7); (2) ischemic surgery followed by saline 
treatment as vehicle control (n = 6); (3) sham operation followed 
by saline treatment (n = 4), and (4) sham operation followed by 
GHB treatment (n = 6). Five weeks after surgery, the animals were 
decapitated under halothane anesthesia, and brains were removed 
immediately and stored at –80  °  C. Since GHB appears to have a 
very narrow dose range in mice, i.e.  1 50 and  ! 150 mg/kg  [14] , 
dosages other than 100 mg/kg were not tested in this study. In ad-
dition, two groups of mice treated (the same protocol as above) for 
3 days either with saline (n = 6) or GHB (n = 6) after ischemic 
surgery were used to assess acute GHB effects on neuronal sur-
vival. In this experiment mice were decapitated 3 days after 
stroke.
 Evaluation of Behavioral Deficits and Motor Recovery
 Prior to surgery and at weekly time points after MCA occlu-
sion, the animal’s body weight was assessed. In order to evaluate 
the animal’s motor recovery, the grip strength test was performed 
prior to surgery and at 1, 3, 5 weeks after MCA occlusion, during 
the light phase (5 h after light onset). The test was conducted on 
the spring balance (Kern 281–401, Kern & Sohn GmbH, Balingen-
Frommern, Gemany) attached to a triangular metal wire as the 
grip bar. Five measurements were averaged at each session (a) for 
the contralateral paretic limb and (b) for both limbs.
 Analysis of Ischemic Brain Injury
 Coronal 16-  m cryostat sections were collected from brains 
at the level of the striatum. Sections were fixed with 0.1  M phos-
phate-buffered saline containing 4% paraformaldehyde for 20 
min at room temperature. Cresyl violet staining was performed 
to outline the damaged area. Adjacent sections were used for im-
munofluorescence staining against the neuronal marker NeuN 
(Chemicon, Temecula, Calif., USA) and the astrocyte marker gli-
al fibrillary acidic protein (GFAP; Dako, Glostrup, Denmark). Af-
ter incubation with the antibody to NeuN (a mouse antibody,
1:  200) or to GFAP (a rabbit antibody, 1:  5,000) at 4  °  C overnight, 
sections were incubated with Cy3-conjugated secondary anti-
body (1:  300; Jackson Immunoresearch, West Grove, Pa., USA). 
Stained sections were analyzed with a Zeiss Axioplan 2 micro-
scope (Carl Zeiss, Jena, Gemany) by counting the density of 
NeuN-positive neurons in the striatum in a total of 12 regions of 
interest, each measuring 62,500   m (500   m apart). Cell count-
ing was conducted by 2 individuals. Neuronal survival in the isch-
emic striatum was finally expressed as percentage by dividing the 
values obtained by cell densities determined in the nonischemic 
striatum  [15] . The NIH image J software was used to analyze in-
jury size.
 Taqman  Gene Expression Assay
 From a 2-mm brain slice obtained from the brain after collect-
ing cryosections, 4 small blocks, containing the striatum and cor-
tex, were carefully dissected both ipsilateral and contralateral to 
the stroke. Blocks were pooled together for each treatment group. 
Total RNA was extracted by the Trizol  method (Life Technolo-
gies, Rockville, Md., USA) and was treated with RQ1 DNase (Pro-
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mega, Madison, Wisc., USA) to digest genomic DNA. Oligo(dT) 15 -
primed first-strand cDNA synthesis was performed with AMV 
reverse transcriptase (Promega). The 5  -FAM TM  label probes used 
in the Taqman real-time quantitative RT-PCR assay for GAPDH 
(endogenous control), GAP43, c-JUN, ephrin B1 and neurocan 
were purchased from Applied Biosystems (Forster City, Calif., 
USA). Reactions were performed in triplicate on a 7900HT fast 
real-time PCR system (Applied Biosystems). The relative level of 
mRNA expression in a given brain area was calculated as follows: 
mRNA = 2 –(  C T  GHB or saline –   C T  sham) , where   C T  = (C T target  – 
C T GAPDH ).
 Statistics
 All data were presented as means  8 SD. Repeated-measures 
ANOVA and one-way ANOVA (SPSS, 12.01 for Windows) were 
used where appropriate, followed by post hoc (Tukey HSD) com-
parison. The 2-sided independent t test was used to estimate 
group differences and the corresponding 95% confidence inter-
vals (95% CI). The significance level was set at p  ^  0.05.
 Results
 Effects of GHB on Behavioral Recovery
 Focal cerebral ischemia led to a reduction of the body 
weight in both saline- and GHB-treated mice ( fig. 1 a). 
During recovery, GHB-treated mice showed much quick-
er regain of body weight to the presurgery level (at 2 
weeks) than saline-treated mice (at 4 weeks). Repeated-
measures ANOVA showed a significant effect of week  ! 
treatment (F 8.4, 53.4  = 4.7, p  ! 0.001). There was a signifi-
cant difference between the ischemia + GHB and isch-
emia + saline group for the second week (95% CI 0.16–
2.55, p = 0.048) and the fifth week (95% CI 0.09–4.39,
p = 0.043).
 The grip strength test ( fig. 1 b) revealed a remarkable 
decrease in motor force of the paretic forelimb after focal 
cerebral ischemia in saline- and GHB-treated mice. A 
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 decrease was also observed when both forelimbs were 
 simultaneously tested. Over the recovery period, GHB 
accelerated restitution of grip strength in the paretic 
 forelimb. Two-way repeated-measures ANOVA showed
a significant effect of week  ! treatment for the paretic 
forelimb (F 9, 57  = 3.1, p = 0.004) and for both forelimbs
(F 9, 54  = 2.68, p = 0.012). A significant difference was de-
tected between the ischemia + GHB and ischemia + sa-
line group in the paretic limb at 3 weeks by independent 
Student t tests (95% CI 5.1–22.9, p = 0.005).
 Effects of GHB on Ischemia-Induced Brain Injury
 As described before  [13] , cresyl violet staining showed 
that a 30-min MCA-induced localized ischemic lesion 
was confined to the striatum ( fig. 2 a). The lesion size in 
the GHB group was 0.77  8 0.21 mm 2  and in the saline 
group 0.65  8 0.28 mm 2 , with a slightly unfavorable effect 
for the GHB group (95% CI –0.39 to 0.17, p = 0.41). Neu-
ronal survival in the injured striatum, calculated by 
NeuN-positive cells ( fig. 2 b), was 48.7  8 9.1% in the saline 
versus 41.0  8 5.9% in the GHB group 5 weeks after isch-
emia, and 46  8 27% versus 42  8 29% in the GHB group 
3 days after ischemia. The difference of the reactive GFAP 
area ( fig. 2 c) in the injury site between the two groups 
(0.99  8 0.48 mm 2  in the saline vs. 1.24  8 0.35 mm 2  in 
the GHB group) appeared also small (95% CI: –0.76 to 
0.26, p = 0.3). Taken together, these results suggest that 
after ischemic stroke the GHB treatment at the dose of 100 
mg/kg has little effect on the brain damage in mice.
 Effects of GHB on Expression of Plasticity-Related 
Genes
 To investigate whether the brain plasticity was re-
sponsible, at least in part, for the beneficial effects of 
 Fig. 2. Effects of GHB on brain injury 5 
weeks after focal cerebral ischemia.  a Sche-
matic drawings illustrating the localiza-
tion of brain damage (shadow area in the 
striatum) after 30 min of MCA occlusion. 
 b NeuN-positive cells in the damaged stri-
atum (shadow area in  a ). Bar = 12   m.
 c GFAP-immunoreactive area in the dam-
aged striatum (shadow area in  a ). Bar = 150 
  m. 
 a 
 b 
 c 
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GHB, a quantitative real-time PCR assay was performed 
for expression of several ischemia-induced genes  [12] . 
The results ( fig. 3 ) revealed that, at the mRNA level, ex-
pression of c- jun, ephrin B1 and neurocan in all regions 
was increased in both ischemia groups treated with ei-
ther saline or GHB ( fig. 3 ). When compared with the 
saline group, GHB-treated mice exhibited reduced ex-
pression for c- jun (13.5  8 1.8 for saline vs. 8.9  8 0.4 for 
GHB, 95% CI 1.9–7.3, p = 0.005) and neurocan (6.7  8 
0.8 for saline vs. 4.1  8 0.2 for GHB, 95% CI 1.3–3.7, p = 
0.001) in the ischemic striatum. The neurocan mRNA 
level in the ischemic cortex was slightly reduced by GHB 
(4.7  8 0.1 for saline vs. 4.1  8 0.08 for GHB, 95% CI 
0.6–0.07, p = 0.001), whereas ephrin B1 was slightly in-
creased (3.2  8 0.3 for saline vs. 3.8  8 0.05 for GHB, 95% 
CI –0.6 to 0.2, p = 0.035).
 Discussion
 In summary, GHB treatment at a small dose similar to 
that used in patients, beginning at reperfusion after isch-
emic stroke, (1) accelerates regain of body weight and re-
covery of the forelimb muscle strength ( fig. 1 ), (2) has no 
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appreciated neuroprotective effects ( fig. 2 b, c) and (3) al-
ters expression of several neuroplasticity-related genes 
( fig. 3 ).
 The finding that GHB accelerates recovery of the mus-
cle strength after stroke in the mouse is consistent with 
previous reports from rat models of ischemia/brain dam-
age that GHB improves sensorimotor activities and learn-
ing memory performance  [6–8] . The GHB-promoted 
rapid regain of body weight observed in this study may 
contribute to the motor strength recovery of both fore-
limbs ( fig. 1 b). However, the GHB-induced significantly 
quicker recovery in the paretic limb (compared to saline 
at 3 weeks) appears a specific effect on the neural tissue, 
since the muscle strength in the sham + GHB group re-
mained unchanged during this period ( fig. 1 b).
 To our surprise, GHB at the dose used in this study 
had little effects on the brain damage evaluated by cresyl 
violet staining, NeuN-positive cell counting and GFAP 
reaction ( fig. 2 ). This observation is in contrast with pre-
vious reports that GHB reduces neuronal loss in rats  [5–
8] . Different animal species and higher GHB dosages 
used in these previous studies may explain the discrep-
ancy. For example, Lavyne et al.  [5] used a protocol in 
which 12 injections of 100 mg/kg of GHB were given at 
2-hour intervals within 24 h. Vergoni et al.  [6] and Ottani 
et al.  [7] used 300 mg/kg for the first injection after the 
stroke surgery. These doses are much higher than those 
used in clinical practice (60–130 mg/kg, daily) and may 
induce a coma-like state in mice  [14] .
 Interestingly, GHB changes expression profiles of sev-
eral neuroplasticity-associated genes in the injured stria-
tum and the nearby region ( fig. 3 ). GHB tends to suppress 
the stroke-evoked increase in expression of these genes, 
and c- jun and neurocan genes in the ischemic striatum 
are the most affected (reduction by 2- to 4-fold;  fig. 3 ). As 
a component of transcription factor AP-1, c- jun is highly 
inducible in response to neuronal injury  [16] and has a 
dual function in both neuron death and survival after 
stroke  [17] . Neurocan is a family member of chondroitin 
sulfate proteoglycans and an inhibitory extracellular ma-
trix molecule. The increase in expression of chondroitin 
sulfate proteoglycans is believed to play a crucial part in 
hindering axon outgrowth  [18] . It is not clear at present 
how GHB-induced changes in expression of neuroplas-
ticity-related genes may influence neuronal tissue repair 
at the cellular level.
 GHB is a reliable sleep stimulant  [2] which at present 
is used to treat narcolepsy-related sleep-wake disorders. 
Sleep is thought to facilitate neuroplasticity in normal 
subjects  [19, 20] and may play a role in mediating func-
tional recovery after stroke  [21] . Further studies are nec-
essary to clarify the relationship between sleep and stroke 
recovery, and the potential role of GHB in promoting 
stoke recovery.
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